CX3CL1 and metabolic syndrome: At 3 months of treatment, CX3CL1 levels were higher in patients with hypertension (1.1 ± 0.1 vs. 0.9 ± 0.1 ng/mL; p = 0.070) or metabolic syndrome (1.1 ± 0.1 vs. 0.9 ± 0.1 ng/mL; p = 0.047).